{"disease":{"id":"intractable-epilepsy","name":"intractable epilepsy"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04649008","title":"Localizing Epileptic Networks Using MRI and iEEG","phase":"EARLY_PHASE1","overall_status":"RECRUITING","enrollment_count":290,"lead_sponsor_name":"University of Pennsylvania","has_results":false},{"nct_id":"NCT06602570","title":"The Mosaic Brain: a New Diagnostic Approach in Focal Epilepsies","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Institute of Child Health","has_results":false},{"nct_id":"NCT03196271","title":"Ketogenic Diet Drink Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":26,"lead_sponsor_name":"Nutricia UK Ltd","has_results":false},{"nct_id":"NCT05600738","title":"Network Effects of Therapeutic Deep Brain Stimulation","phase":"NA","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"The University of Texas Health Science Center, Houston","has_results":false},{"nct_id":"NCT04810832","title":"EXPRESON-IN : Intracerebral Recordings of P3a Responses to Expressive Own-names","phase":"NA","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"Centre Hospitalier St Anne","has_results":false},{"nct_id":"NCT03955432","title":"Long-term Cardiac Monitoring in Epilepsy","phase":"NA","overall_status":"TERMINATED","enrollment_count":7,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT03860298","title":"Safety of Using NaviFUS System in Patients With Drug Resistant Epilepsy","phase":"NA","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"NaviFUS Corporation","has_results":false},{"nct_id":"NCT04650204","title":"Perampanel for the Reduction of Seizure Frequency in Patients With High-grade Glioma and Focal Epilepsy","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Mayo Clinic","has_results":true},{"nct_id":"NCT02934854","title":"Biomarker for Creatine Deficiency Syndromes (BioCDS)","phase":"","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"CENTOGENE GmbH Rostock","has_results":false}],"total":9},"guidelines":[],"source":"Drug Landscape verified database"}